Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib + isoquercetin for hospitalized moderate to severe COVID-19
2020-001635-27Phase 2Active
- Sponsor
- AB Science
- Start
- Apr 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Masitinib + isoquercetin + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Clinical status at day 15. Started Apr 2020; status: active.
02
Drugs
masitinibisoquercetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001635-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001635-27.